Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Metrics to compare | CUV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCUVPeersSector | |
---|---|---|---|---|
P/E Ratio | 16.2x | −2.5x | −0.6x | |
PEG Ratio | 0.51 | −0.05 | 0.00 | |
Price/Book | 2.9x | 2.1x | 2.6x | |
Price / LTM Sales | 6.9x | 12.5x | 3.3x | |
Upside (Analyst Target) | 82.8% | 325.6% | 39.1% | |
Fair Value Upside | Unlock | −7.5% | 5.4% | Unlock |